Top 20 BioPharma Companies based on 2021 Total Revenue
- While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios
- While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also entered the list and, with massive growth in their revenue
- J&J remains at the top with a revenue of $93.80B, followed by Pfizer & Roche with $81.30B & $69.84B, respectively. PharmaShots has compiled a list of the top 20 biopharma companies based on their 2021 total revenue
Total Revenue: $17.89B
Pharma Segment Revenue: $17.89B
Founded Year: 2019
Market Cap: $13.29B
Total Employees: ~40,000
Non-Pharma Segment Revenue: Nil
Headquarters: Canonsburg, United States
Stock Exchange: NASDAQ
Viatris is a global healthcare company formed by the merger of Mylan and Upjohn (generics division of Pfizer) that deals with generics, biosimilars, and over-the-counter products. Viatris' 2021 revenue shoots up to 50% vs. 2020. In Nov 2021, Viatris, with Biocon, launched biosimilar Insulin Glargine - Semglee for Type 1 Diabetes.
Total Revenue: $18.47B
Pharma Segment Revenue: $18.47B
Founded Year: 2010
Market Cap: $68.38B
Total Employees: ~1300
Non-Pharma Segment Revenue: Nil
Headquarters: Massachusetts, United States
Stock Exchange: NASDAQ
Moderna is an American Biopharma company focused on RNA therapeutics and developing mRNA vaccines. Moderna's 2021 revenue rocket to 2,200% vs 2020. In 2021, Moderna entered into multiple agreements and deals for its COVID-19 vaccine.
Total Revenue: $21.53B
Pharma Segment Revenue: $21.53B
Founded Year: 1923
Market Cap: $210.04B
Total Employees: ~48,478
Non-Pharma Segment Revenue: Nil
Headquarters: Bagsvaerd, Denmark
Stock Exchange: Copenhagen
Novo Nordisk is a global healthcare company, a leader in diabetes and obesity care. Novo Nordisk's 2021 revenue grew to 11 % vs. 2020. In 2021, Novo Nordisk had two significant acquisitions. Its largest investment was in Dec 2021, when it acquired Dicerna Pharmaceuticals for $3.3B, and then in July 2021, it purchased Prothena's ATTR amyloidosis business for $1.2B.
Total Revenue: $21.58B
Pharma Segment Revenue: $21.58B
Founded Year: 2008
Market Cap: $44.27B
Total Employees: ~1941
Non-Pharma Segment Revenue: Nil
Headquarters: Mainz, Germany
Stock Exchange: NASDAQ
BioNTech is a German biotechnology company that develops next-generation immunotherapies for cancer and other serious diseases. BioNTech's 2021 revenue soared to 3834.6% vs. 2020. In Nov 2021, Pfizer and BioNTech's Comirnaty received CHMP's positive opinion for the treatment of COVID-19 in children aged 5 to 12 years.
Total Revenue: $22.39B
Pharma Segment Revenue: $8.06B
Founded Year: 1668
Market Cap: $26.64B
Total Employees: ~60,348
Non-Pharma Segment Revenue: $15.4B
Headquarters: Darmstadt, Germany
Stock Exchange: ETR
The Merck Group (Merck KGaA) is a German multinational science and technology company focused on oncology- immuno-oncology- and neurology & immunology. Merck KGaA's 2021 revenue increased by 12.3% vs. 2020. In Mar 2021, Merck KGaA signed an exclusive worldwide license agreement with Debiopharm for Xevinapant
Total Revenue: $25.97B
Pharma Segment Revenue: $25.97B
Founded Year: 1980
Market Cap: $135.32B
Total Employees: ~24,200
Non-Pharma Segment Revenue: Nil
Headquarters: California, United States
Stock Exchange: NASDAQ
Amgen is an American Biopharma company headquartered in Thousand Oaks, California. Amgen's 2021 revenue increased by 2% vs. 2020. In Oct 2021, Amgen completed its acquisition of Teneobio for ~$2.5B. In addition, in Dec 2021, Janssen and Amgen's Darzalex Faspro (daratumumab and hyaluronidase-fihj) received the US FDA's approval to treat multiple myeloma.
Total Revenue: $27.30B
Pharma Segment Revenue: $27.3B
Founded Year: 1987
Market Cap: $77.93B
Total Employees: ~60,348
Non-Pharma Segment Revenue: Nil
Headquarters: California, United States
Stock Exchange: NASDAQ
Gilead Sciences is a research-based biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. Gilead's 2021 revenue increased by 11% vs. 2020. In Mar 2021, Gilead collaborated with Merck to jointly develop and commercialize Lenacapavir + Islatravir for HIV and received Epclusa (Sofosbuvir/Velpatasvir) approval from the US FDA for children with chronic hepatitis C infection in Jun 2022.
Total Revenue: $28.31B
Pharma Segment Revenue: $28.31B
Founded Year: 1876
Market Cap: $288.25B
Total Employees: ~35,238
Non-Pharma Segment Revenue: Nil
Headquarters: Indiana, United States
Stock Exchange: NYSE
Eli Lilly is an American pharma company that focuses on developing, manufacturing, and marketing human pharmaceutical products. Lilly's total revenue increased by 15% in 2021. Lilly's Verzenio (abemaciclib) received the US FDA's approval for people with HR+ HER2- high-risk early breast cancer in Oct 2021 and collaborated with Kumquat Biosciences to discover and develop novel small molecules that stimulate tumor-specific immune responses in July 2021.
Total Revenue: $37.41B
Pharma Segment Revenue: $37.41B
Founded Year: 1999
Market Cap: $211.65B
Total Employees: ~76,100
Non-Pharma Segment Revenue: Nil
Headquarters: Cambridge, United Kingdom
Stock Exchange: LON
AstraZeneca is a global pharmaceutical focusing on Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology. AstraZeneca's total revenue increased by 41% vs. 2020. In 2021, AstraZeneca launched 13 blockbuster drugs and collaborated with Ionis to develop and commercialize Eplontersen to treat transthyretin amyloidosis. In addition, the company witnessed 22 regulatory approval and authorizations in significant markets.
Total Revenue: $42.95B
Pharma Segment Revenue: $42.95B
Founded Year: 1973
Market Cap: $141.35B
Total Employees: ~95,442
Non-Pharma Segment Revenue: Nil
Headquarters: Paris, France
Stock Exchange: EPA
Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries worldwide. Sanofi's 2021 revenue increased 4.8% vs. 2020 revenue. In Sep 2021, Sanofi acquired Kadmon for ~$1.9B, which included transplant business with the addition of Kadmon's Rezurock to treat patients with cGVHD. The company has also acquired Translate Bio for ~$3.2B to utilize mRNA technology which accelerated Sanofi's licensed programs to develop transformative therapies & vaccines in Aug 2021.
Total Revenue: $43.07B
Pharma Segment Revenue: $4.71B
Founded Year: 1888
Market Cap: $210.70B
Total Employees: ~1,13,000
Non-Pharma Segment Revenue: 38.36
Headquarters: Illinois- United States
Stock Exchange: NYSE
Abbott Laboratories is an American multinational medical devices and healthcare company with four segments: Established Pharmaceutical and Nutritional Products, Diagnostics, and Medical Devices. Abbott's 2021 revenue showed an increase of 24.5% vs. 2020. Abbott's Amplatzer Amulet device received the US FDA's approval for the treatment of atrial fibrillation in Aug 2021.
Total Revenue: $46.17B
Pharma Segment Revenue: $46.17B
Founded Year: 1873
Market Cap: $118.23B
Total Employees: ~90,096
Non-Pharma Segment Revenue: Nil
Headquarters: Brentford, United Kingdom
Stock Exchange: LON
GSK is a global healthcare company focused on prescription medicines, vaccines & consumer healthcare products and is a leader in the areas of respiratory and HIV. GSK's 2021 increased by 5% as compared to 2020 revenue. In Jun 2021, GSK collaborated with iTeos to develop and commercialize EOS-448 for patients with cancer.
Total Revenue: $46.38B
Pharma Segment Revenue: $46.38B
Founded Year: 1887
Market Cap: $163.36B
Total Employees: ~32,200
Non-Pharma Segment Revenue: Nil
Headquarters: New York, United States
Stock Exchange: NYSE
Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on oncology, cardiovascular, and immunology. BMS's 2021 revenue increased by 9% vs. 2020. In Dec 2021, BMS' Orencia (abatacept) received the US FDA's approval to prevent acute graft versus host disease. In Jun 2021, it collaborated with Eisai for the development & co-commercialization of MORAb-202.
Total Revenue: $48.70B
Pharma Segment Revenue: $42.75B
Founded Year: 1891
Market Cap: $217.77B
Total Employees: ~68,000
Non-Pharma Segment Revenue: $ 5.95B
Headquarters: New Jersey, United States
Stock Exchange: NYSE
Merck & Co. is a global healthcare company focused on innovative health solutions by prescription medicines, vaccines, biological therapies, and animal health products. Merck & Co.'s 2021 revenue increased by 17% vs. 2020. In Sep 2021, Merck acquired Acceleron for $11.5B, strengthening its cardiovascular pipeline.
Total Revenue: $50.14B
Pharma Segment Revenue: $26.89B
Founded Year: 1863
Market Cap: $72.04B
Total Employees: ~99,637
Non-Pharma Segment Revenue: $22.99B
Headquarters: New Jersey, United States
Stock Exchange: ETR
Bayer is a global life science and healthcare company with three divisions- pharmaceuticals, consumer health, and crop science. Bayer's 2021 revenue increased by 6.5 % vs. 2020. In Aug 2021, Bayer acquired Vividion for ~$2B, which strengthened its drug discovery capabilities & expanded it into new modalities
Total Revenue: $51.62
Pharma Segment Revenue: $51.62
Founded Year: 1996
Market Cap: $226.14B
Total Employees: ~10,800
Non-Pharma Segment Revenue: Nil
Headquarters: Basel, Switzerland
Stock Exchange: Six Swiss Exchange-NYSE
Novartis is a multinational biopharma company focused on research, development, manufacturing, and marketing of a range of healthcare solutions, including generic and ophthalmic therapies. Novartis' 2021 revenue showed an increase of 8 % vs. 2020. In Dec 2021, Novartis strengthened its immunotherapy pipeline by collaborating with BeiGene for the TIGIT inhibitor, Ociperlimab
Total Revenue: $56.19
Pharma Segment Revenue: $56.19
Founded Year: 2013
Market Cap: $280.75B
Total Employees: ~50,000
Non-Pharma Segment Revenue: Nil
Headquarter: Illinois, United States
Stock Exchange: NYSE
AbbVie is a research-based global Biopharma company focused on developing therapies for chronic autoimmune diseases, oncology, and virology, with additional targets like cystic fibrosis and women's health. It has an enriched pipeline in immunology and neuroscience. AbbVie's 2021 revenue increased by 23 % vs. 2020. In Sep 2021, AbbVie collaborated with Regenxbio to develop and commercialize RGX-314 to treat retinal diseases.
Total Revenue: $69.84
Pharma Segment Revenue: $49.39
Founded Year: 1894
Market Cap: $341.52B
Total Employees: ~1,00,920
Non-Pharma Segment Revenue: $20.45
Headquarters: Basel, Switzerland
Stock Exchange: Six Swiss Exchange
Roche is a Swiss multinational healthcare company focused on pharmaceuticals and diagnostics divisions. Roche's 2021 increased by 9 % vs. 2020. In Aug 2021, Roche collaborated with Shape Therapeutics to develop gene therapies for Alzheimer's, Parkinson's, and rare diseases.
Total Revenue: $81.3
Pharma Segment Revenue: $81.3
Founded Year: 1849
Market Cap: $299.90B
Total Employees: ~1,21,831
Non-Pharma Segment Revenue: Nil
Headquarters: New York, United States
Stock Exchange: NYSE
Pfizer is a research-based global Biopharma company. In Apr 2020, it collaborated with BioNTech to develop, manufacture, and commercialize an mRNA-based coronavirus vaccine program, BNT162, to prevent COVID-19. Pfizer's 2021 revenue increased by 95.16 % vs.2020. In Dec 2021, Pfizer acquired Arena for ~ $6.7B and Trillium for ~$2.26B in Aug 2021.
Total Revenue: $93.8
Pharma Segment Revenue: $66.7
Founded Year: 1886
Market Cap: $475.07B
Total Employees: ~1,41,700
Non-Pharma Segment Revenue: $27.1
Headquarters: New Jersey, United States
Stock Exchange: NYSE
Johnson & Johnson (J&J) is an American multinational healthcare company focused on developing and commercializing pharmaceuticals, medical devices, and consumer packaged products. J&J's 2021 revenue increased by 13.6 % vs. 2020. In Nov 2021, the company planned to spin off its consumer health division to serve patients and consumers & unlocked value through the intent to separate the consumer health business.
$: All revenues are reported in USD.
Sources:
- Annual reports,
- SEC filings,
- Press releases,
- Company websites
Market Cap Source: Google finance (as of 13 April 2022)
Note: Takeda & Boehringer Ingelheim is not included in the top 20 list, as its actual revenue was not available. The data is collected as of 13 April 2022.
Related Post: Top 20 BioPharma Companies based on 2020 Total Revenue
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com